PHOSPHOLIPASE A2

CAS: 9001-84-7 | EC No.: 232-637-7

PHOSPHOLIPASE A2 (PLA2 or PA2) is an enzyme derived from porcine pancreas. It serves as a catalyst in the hydrolysis of the fatty acid in the second position of phospholipids/lecithin.  This process converts approximately 70% of the lecithin found in egg yolk to lysolecithin, which has much better emulsifying properties than lecithin.

Advantages:

Phospholipase A2 from porcine pancreas offers distinct functional advantages over plant-derived and microbial alternatives. Its high specificity for the sn-2 position ensures clean, controlled hydrolysis of phospholipids with minimal side reactions, yielding lysolecithins of consistent quality and superior emulsifying power.

In egg-yolk processing, PLA2-modified yolk withstands temperatures of 70–80 °C and, in mayonnaise systems, above 150 °C dramatically extending thermal processing options, microbiological safety and product shelf life compared with native yolk. The resulting increase in viscosity and emulsion stability reduces the need for synthetic additives, supporting cleaner-label formulations across mayonnaise, sauces, dairy, bakery and beverages. In oil refining, porcine PLA2 delivers highly efficient enzymatic degumming, lowering phosphorus levels and reducing chemical inputs versus conventional acid degumming.

In coffee and cocoa-based systems, PLA2 hydrolysis of native lipids and phospholipids reduces unwanted surface oiling, improves beverage clarity and generates lyso-phospholipids that enhance crema formation, foam stability and perceived creaminess in espresso drinks, hot chocolate and ready-to-drink beverages. The controlled enzymatic action also limits undesirable lipid oxidation, helping preserve the characteristic aroma profiles of coffee and chocolate over shelf life.

In pharmaceutical development, the well-characterised sn-2 specificity of porcine PLA2 makes it an ideal trigger for smart drug-delivery systems. PLA2-responsive liposomes, micelles and nanoparticles exploit elevated enzyme levels at tumour and inflammatory sites to achieve selective carrier destabilisation and site-specific drug release. This mechanism supports advanced applications including dual-responsive nanocarriers (PLA2 + pH), theranostic platforms combining therapy with real-time imaging, and localised delivery of PLA2 inhibitors to modulate pathological inflammation.

Bioseutica®'s enzyme preparation meets the purity criteria established by JECFA and the Food Chemical Codex (FCC), with all raw materials sourced from government-certified facilities to ensure full traceability and global regulatory compliance. Neova Technologies provides end-to-end technical support, from formulation and dosage optimisation through to industrial scale-up, to help clients maximise performance in their specific application.

Applications:

Phospholipase A2 (PLA2) is used to produce enzyme-modified egg yolk with superior functional performance for the food industry. Treated egg yolk delivers markedly higher emulsifying capacity, enabling stable incorporation of fat and water phases in mayonnaise, sauces, dressings, baked goods and ice cream. Thermal resistance is dramatically improved: PLA2-modified yolk remains stable at 70–80 °C, well above the approximately 60 °C limit of native yolk, and in mayonnaise formulations has withstood retort temperatures exceeding 150 °C, making full pasteurisation feasible for enhanced microbiological safety and longer shelf life. The enzyme treatment also increases viscosity, a critical quality attribute in mayonnaise and sauce production where body, texture and consumer-perceived creaminess directly influence product acceptance.

In coffee and cocoa-based applications, PLA2 modifies native lipids and naturally occurring phospholipids to improve beverage clarity and eliminate surface oiling in soluble, espresso-style and ready-to-drink coffees as well as liquid chocolate and cocoa beverages. The lyso-phospholipids generated by enzymatic hydrolysis enhance crema formation, foam stability, body and perceived creaminess in foamed coffee drinks and hot chocolate. PLA2 treatment also stabilises coffee-milk, coffee-oil, cocoa-milk and cocoa-oil emulsions, reducing phase separation during processing and storage while limiting lipid oxidation pathways responsible for off-flavour development, helping preserve clean coffee aroma and characteristic chocolate flavour throughout shelf life.

In the pharmaceutical field, PLA2 is increasingly employed as an enzyme-responsive trigger in advanced drug-delivery systems. PLA2-responsive liposomes and phospholipid micelles release encapsulated drugs, such as antibiotics or anticancer agents, when they encounter the elevated PLA2 concentrations found at sites of infection, tumour growth or chronic inflammation. The lysophospholipids and fatty acids generated during membrane hydrolysis increase local permeability, enhancing cellular uptake of the released payload. This mechanism underpins a growing range of smart nanocarrier designs, including dual-responsive systems (PLA2 + pH), theranostic platforms that combine targeted therapy with real-time imaging, and nanoparticles loaded with PLA2 inhibitors for localised modulation of pathological inflammation in cardiovascular, joint and neuro-inflammatory conditions.

Food Applications:

PHOSPHOLIPASE A2 is used extensively as a processing aid in many food applications, including:

• Production of enzyme‑modified, heat‑stable egg yolk for use in mayonnaise.

• Improved emulsification, viscosity and thermal stability in mayonnaise, enabling pasteurization and extended shelf life.

• Enzymatic degumming of vegetable oils to remove phospholipids and improve refining efficiency.

• Lecithin and egg yolk powder hydrolysis to produce lysolecithins with enhanced emulsifying power.

• Production of low‑fat cheese and other dairy products with improved texture and creaminess.

• Improving the heat stability and emulsifying properties of egg yolk and soy products in sauces, dressings and beverages.

• Enhancing antibacterial activity against both GRAM‑positive and GRAM‑negative bacteria in certain formulations.

• Preventing oiling‑out during cheese production, thereby increasing yield and product consistency.

• Stabilising oil‑in‑water emulsions in food and beverage systems, helping to reduce phase separation and improve mouthfeel.

• Tailoring functional phospholipid ingredients (e.g. for bakery, confectionery and ready‑to‑drink beverages) to optimise body, creaminess and shelf‑life.

Coffee and Cocoa-based Applications:

In coffee and cocoa‑based applications, PHOSPHOLIPASE A2 can also be used to:

• Modify coffee and cocoa lipids and naturally occurring phospholipids to improve beverage clarity and reduce surface oiling in soluble and ready‑to‑drink coffees, liquid chocolate products and cocoa beverages.

• Generate lyso‑phospholipids that enhance cream formation, foam stability, body and perceived creaminess in espresso‑style and foamed coffee drinks, hot chocolate and chocolate‑flavored beverages.

• Improve the physical stability of coffee‑milk, coffee‑oil, cocoa‑milk and cocoa‑oil emulsions, limiting phase separation during processing and storage.

• Reduce the development of off‑flavours linked to uncontrolled lipid degradation, helping maintain a cleaner and more stable coffee aroma and characteristic chocolate aroma over shelf‑life.

Pharmaceutical Applications:

PHOSPHOLIPASE A2 has a variety of applications in drug delivery systems, particularly as an enzyme‑responsive trigger in lipid‑based carriers:

• Enabling PLA2‑responsive liposomes that release encapsulated drugs (e.g. antibiotics or anticancer agents) when they encounter elevated PLA2 levels at sites of infection or tumors.

• Designing PLA2‑degradable liposomes and phospholipid micelles in which enzymatic hydrolysis of membrane lipids destabilizes the carrier and accelerates drug release.

• Targeting cancers and inflammatory diseases where secretory PLA2 is overexpressed, using PLA2 activity in the local tissue microenvironment as a selective trigger for site‑specific drug release.

• Increasing membrane permeability at the target site through the lysophospholipids and fatty acids generated by PLA2, thereby enhancing cellular uptake of released drugs.

• Supporting smart nanocarrier designs (liposomes, micelles, nanoparticles) that combine PLA2‑sensitive phospholipids with imaging agents or prodrugs for theranostic or controlled‑release applications.

• Developing PLA2‑responsive nanoparticles and micelles for tumor‑targeted chemotherapy and combination therapies, often in dual‑responsive systems (e.g. PLA2 + pH) to better exploit the tumor microenvironment.

• Creating PLA2‑responsive nanocarriers that co‑deliver imaging agents (e.g. MRI contrast or optical probes) and drugs, enabling real‑time tracking of drug accumulation and release.

• Formulating nanoparticles loaded with PLA2 inhibitors to locally modulate pathological inflammation in diseases where PLA2 is up-regulated (e.g. certain joint, cardiovascular or neuro-inflammatory conditions).

Regulatory:

Regulations may vary by country. Always check the local legislation regarding the usage and claims of this product.

Specifications (units/ml):

PHOSPHOLIPASE A2 Activity Min: 10,000